Aprea Therapeutics (NASDAQ:APRE) Given Outperform Rating at Wedbush

Wedbush reissued their outperform rating on shares of Aprea Therapeutics (NASDAQ:APRE) in a research note issued to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $7.00 target price on the stock.

A number of other research analysts have also recently issued reports on APRE. Weiss Ratings restated a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Wednesday, January 21st. HC Wainwright reduced their price target on shares of Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Zacks Research raised shares of Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, February 16th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Aprea Therapeutics has an average rating of “Hold” and a consensus price target of $4.10.

Aprea Therapeutics Trading Up 3.2%

Shares of APRE opened at $0.76 on Tuesday. The stock has a market cap of $8.74 million, a P/E ratio of -0.39 and a beta of 1.42. Aprea Therapeutics has a 1 year low of $0.55 and a 1 year high of $2.30. The stock’s 50-day moving average price is $0.76 and its two-hundred day moving average price is $1.05.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings results on Monday, March 16th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.06. The company had revenue of $0.00 million during the quarter. Aprea Therapeutics had a negative return on equity of 96.33% and a negative net margin of 4,405.59%. As a group, equities analysts forecast that Aprea Therapeutics will post -2.55 EPS for the current year.

Hedge Funds Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Jane Street Group LLC bought a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned 0.67% of Aprea Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.